Marlie Vipond

Marlie Vipond

Auto-generated profile, based on publicly available information

Marlie Vipond

International Center for Polyamine Disorders Grand Rapids MI USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2023 in Developmental Medicine & Child Neurology
Verified
Journal Article
Open access
ABAndré S. Bachmann
André S. Bachmann
EVElizabeth A. VanSickle
Elizabeth A. VanSickle
JMJulianne Michael
Julianne Michael
MVMarlie Vipond
Marlie Vipond
Caleb BuppCaleb Bupp
Caleb Bupp
Bachmann–Bupp syndrome (BABS) is a neurodevelopmental disorder characterized by developmental delay, hypotonia, and varying forms of non‐congenital alopecia. The condition is caused by 3′‐end mutations of the ornithine decarboxylase 1 (ODC1) gene, which produce carboxy (C)‐terminally truncated variants of ODC, a pyridoxal 5′‐phosphate‐dependent enzyme. C‐terminal truncation of ODC prevents its ubiquitin‐independent proteasomal degradation and leads to cellular accumulation of ODC enzyme that remains catalytically active. ODC is the first rate‐limiting enzyme that converts ornithine to putrescine in the polyamine pathway. Polyamines (putrescine, spermidine, spermine) are aliphatic molecules found in all forms of life and are important during embryogenesis, organogenesis, and tumorigenesis. BABS is an ultra‐rare condition with few reported cases, but it serves as a convincing example for drug repurposing therapy. α‐Difluoromethylornithine (DFMO, also known as eflornithine) is an ODC inhibitor with a strong safety profile in pediatric use for neuroblastoma and other cancers as well as West African sleeping sickness (trypanosomiasis). Patients with BABS have been treated with DFMO and have shown improvement in hair growth, muscle tone, and development.